ECSP003652A - TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1 - Google Patents

TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1

Info

Publication number
ECSP003652A
ECSP003652A EC2000003652A ECSP003652A ECSP003652A EC SP003652 A ECSP003652 A EC SP003652A EC 2000003652 A EC2000003652 A EC 2000003652A EC SP003652 A ECSP003652 A EC SP003652A EC SP003652 A ECSP003652 A EC SP003652A
Authority
EC
Ecuador
Prior art keywords
release
combination
processing
inhibit
compounds
Prior art date
Application number
EC2000003652A
Other languages
English (en)
Inventor
Joseph Tardio
Paul Hadvary
Hans Lengsfeld
Hans Steffen
Bruce Henry Littman
Marcel Schmid
Farland Small Donald Mac
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP003652A publication Critical patent/ECSP003652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El invento se refiere a métodos y composiciones para tratar y prevenir estados de enfermedad por la interleuquina 1 (IL-1). En los métodos y las composiciones se usa un polipáptido antagonista del receptor de la interleuquina 1(I1-1ra.), o una variante del mismo, en combinación con un agente no esteroide que inhibe el procesamiento y la liberación del I1-1.
EC2000003652A 1999-09-14 2000-09-12 TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1 ECSP003652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ECSP003652A true ECSP003652A (es) 2002-04-23

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003652A ECSP003652A (es) 1999-09-14 2000-09-12 TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1

Country Status (13)

Country Link
EP (1) EP1214087A1 (es)
JP (1) JP2003509378A (es)
AR (1) AR033650A1 (es)
AU (1) AU6464400A (es)
BR (1) BR0014003A (es)
CA (1) CA2383026A1 (es)
CO (1) CO5190701A1 (es)
EC (1) ECSP003652A (es)
GT (1) GT200000155A (es)
PA (1) PA8502901A1 (es)
PE (1) PE20010685A1 (es)
TN (1) TNSN00183A1 (es)
WO (1) WO2001019390A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
CN109071454B (zh) 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CA3047336A1 (en) 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity
AU2017416068A1 (en) 2017-05-24 2019-10-31 The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Novel compounds and uses
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
US11465992B2 (en) 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
RS65492B1 (sr) 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
MX2020001776A (es) * 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
US20220267276A1 (en) 2018-07-03 2022-08-25 Novartis Ag Nlrp modulators
SG11202012159TA (en) 2018-07-20 2021-01-28 Hoffmann La Roche Sulfonylurea compounds as inhibitors of interleukin-1 activity
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
CN113056451A (zh) 2018-10-24 2021-06-29 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN120208846A (zh) 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物
JP7565628B2 (ja) * 2020-05-25 2024-10-11 ベイジン ブイディージェイバイオ カンパニー， リミテッド インターロイキン－１受容体アンタゴニスト及びそれを含む融合タンパク質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
AU723895B2 (en) * 1997-01-29 2000-09-07 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
PE20010685A1 (es) 2001-07-03
JP2003509378A (ja) 2003-03-11
AU6464400A (en) 2001-04-17
CA2383026A1 (en) 2001-03-22
BR0014003A (pt) 2002-05-21
CO5190701A1 (es) 2002-08-29
EP1214087A1 (en) 2002-06-19
WO2001019390A1 (en) 2001-03-22
TNSN00183A1 (fr) 2005-11-10
GT200000155A (es) 2002-03-08
PA8502901A1 (es) 2002-02-21
AR033650A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
ECSP003652A (es) TRATAMIENTO DE COMBINACION CON I1-1ra Y COMPUESTOS QUE INHIBEN EL PROCESAMIENTO Y LA LIBERACION DE I1-1
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
MX9203444A (es) Medicamentos.
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
CR9842A (es) Composiciones de celecoxib
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
AR031473A1 (es) Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
ATE333896T1 (de) Vaskularisierungsinhibitoren
SV2002000235A (es) Composiciones farmaceuticas que comprenden valdecoxib
PE20010642A1 (es) Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
AR021690A1 (es) Empleo de inhibidores del canal de ktq1 para la preparacion de un medicamento para el tratamiento de enfermedades, que son provocadas por helmintos yectoparasitos.
CO5540294A2 (es) Una combinacion de un derivado de rapamicina y un agente alquilante seleccionado de ciclofosfamida y carmustina y composiciones que las contienen
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
ES2173871T3 (es) Tratamiento de condiciones neurologicas por un compuesto inhibidor de la interleukina-1.
AR034975A1 (es) Metodo para el tratamiento del insomnio primario
UY26336A1 (es) Tratamiento de combinación con i1-1ra y compuestos que inhiben el procesamiento y la liberación de i1-1.
ES2543836T3 (es) Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
AR058298A1 (es) Composicion veterinaria